Search Results - "Williams, Stetson H."

Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers by Raja, Srikumar M., Clubb, Robert J., Ortega-Cava, Cesar, Williams, Stetson H., Bailey, Tameka A., Duan, Lei, Zhao, Xiangshan, Reddi, Alagarasamy L., Nyong, Abijah M., Natarajan, Amarnath, Band, Vimla, Band, Hamid

“…The receptor tyrosine kinase ErbB2 is overexpressed in up to a third of breast cancers, allowing targeted therapy with ErbB2-directed humanized antibodies such…”
Get full text

Negative Regulation of EGFR-Vav2 Signaling Axis by Cbl Ubiquitin Ligase Controls EGF Receptor-mediated Epithelial Cell Adherens Junction Dynamics and Cell Migration by Duan, Lei, Raja, Srikumar M., Chen, Gengsheng, Virmani, Sumeet, Williams, Stetson H., Clubb, Robert J., Mukhopadhyay, Chandrani, Rainey, Mark A., Ying, Guoguang, Dimri, Manjari, Chen, Jing, Reddi, Alagarsamy L., Naramura, Mayumi, Band, Vimla, Band, Hamid

“…The E3 ubiquitin ligase Casitas B lymphoma protein (Cbl) controls the ubiquitin-dependent degradation of EGF receptor (EGFR), but its role in regulating…”
Get full text

Staphylococcus aureus biofilms prevent macrophage phagocytosis and attenuate inflammation in vivo by Thurlow, Lance R, Hanke, Mark L, Fritz, Teresa, Angle, Amanda, Aldrich, Amy, Williams, Stetson H, Engebretsen, Ian L, Bayles, Kenneth W, Horswill, Alexander R, Kielian, Tammy

“…Biofilms are complex communities of bacteria encased in a matrix composed primarily of polysaccharides, extracellular DNA, and protein. Staphylococcus aureus…”
Get full text

Polypeptide-based nanogels co-encapsulating a synergistic combination of doxorubicin with 17-AAG show potent anti-tumor activity in ErbB2-driven breast cancer models by Desale, Swapnil S., Raja, Srikumar M., Kim, Jong Oh, Mohapatra, Bhopal, Soni, Kruti S., Luan, Haitao, Williams, Stetson H., Bielecki, Timothy A., Feng, Dan, Storck, Matthew, Band, Vimla, Cohen, Samuel M., Band, Hamid, Bronich, Tatiana K.

“…ErbB2-driven breast cancers constitute 20–25% of the cases diagnosed within the USA. The humanized anti-ErbB2 monoclonal antibody, Trastuzumab (Herceptin™;…”
Get full text

Continuous requirement of ErbB2 kinase activity for loss of cell polarity and lumen formation in a novel ErbB2/Neu-driven murine cell line model of metastatic breast cancer by Ortega-Cava, Cesar F, Raja, Srikumar M, Laiq, Zenab, Bailey, Tameka A, Luan, Haitao, Mohapatra, Bhopal, Williams, Stetson H, Ericsson, Aaron C, Goswami, Rasna, Dimri, Manjari, Duan, Lei, Band, Vimla, Naramura, Mayumi, Band, Hamid

“…Well over a quarter of human breast cancers are ErbB2-driven and constitute a distinct subtype with substantially poorer prognosis. Yet, there are substantial…”
Get full text

Abstract LB-240: Mechanism-based enhancement of ErbB2-targeted delivery of chemotherapeutics encapsulated in Trastuzumab-conjugated polymeric nanocarriers by Raja, Srikumar M., Kim, Jong Oh, Desale, Swapnil S., Nukolova, Natasha V., Oberoi, Hardeep S., Williams, Stetson H., Luan, Haitao, Band, Vimla, Kabanov, Alexander V., Bronich, Tatiana K., Band, Hamid

“…Abstract ErbB2-driven breast cancers account for 20-25% of Breast Cancer patients screened in the USA. The humanized monoclonal antibody, Trastuzumab…”
Get full text